TY - JOUR
T1 - A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research
T2 - an international Delphi consensus study
AU - PC-COS project steering committee
AU - Munblit, Daniel
AU - Nicholson, Timothy
AU - Akrami, Athena
AU - Apfelbacher, Christian
AU - Chen, Jessica
AU - De Groote, Wouter
AU - Diaz, Janet V
AU - Gorst, Sarah L
AU - Harman, Nicola
AU - Kokorina, Alisa
AU - Olliaro, Piero
AU - Parr, Callum
AU - Preller, Jacobus
AU - Schiess, Nicoline
AU - Schmitt, Jochen
AU - Seylanova, Nina
AU - Simpson, Frances
AU - Tong, Allison
AU - Needham, Dale M
AU - Williamson, Paula R
AU - Aiyegbusi, Olalekan Lee
N1 - Publisher Copyright:
© 2022 World Health Organization. Published by Elsevier Ltd. All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Health consequences that persist beyond the acute infection phase of COVID-19, termed post-COVID-19 condition (also commonly known as long COVID), vary widely and represent a growing global health challenge. Research on post-COVID-19 condition is expanding but, at present, no agreement exists on the health outcomes that should be measured in people living with the condition. To address this gap, we conducted an international consensus study, which included a comprehensive literature review and classification of outcomes for post-COVID-19 condition that informed a two-round online modified Delphi process followed by an online consensus meeting to finalise the core outcome set (COS). 1535 participants from 71 countries were involved, with 1148 individuals participating in both Delphi rounds. Eleven outcomes achieved consensus for inclusion in the final COS: fatigue; pain; post-exertion symptoms; work or occupational and study changes; survival; and functioning, symptoms, and conditions for each of cardiovascular, respiratory, nervous system, cognitive, mental health, and physical outcomes. Recovery was included a priori because it was a relevant outcome that was part of a previously published COS on COVID-19. The next step in this COS development exercise will be to establish the instruments that are most appropriate to measure these core outcomes. This international consensus-based COS should provide a framework for standardised assessment of adults with post-COVID-19 condition, aimed at facilitating clinical care and research worldwide.
AB - Health consequences that persist beyond the acute infection phase of COVID-19, termed post-COVID-19 condition (also commonly known as long COVID), vary widely and represent a growing global health challenge. Research on post-COVID-19 condition is expanding but, at present, no agreement exists on the health outcomes that should be measured in people living with the condition. To address this gap, we conducted an international consensus study, which included a comprehensive literature review and classification of outcomes for post-COVID-19 condition that informed a two-round online modified Delphi process followed by an online consensus meeting to finalise the core outcome set (COS). 1535 participants from 71 countries were involved, with 1148 individuals participating in both Delphi rounds. Eleven outcomes achieved consensus for inclusion in the final COS: fatigue; pain; post-exertion symptoms; work or occupational and study changes; survival; and functioning, symptoms, and conditions for each of cardiovascular, respiratory, nervous system, cognitive, mental health, and physical outcomes. Recovery was included a priori because it was a relevant outcome that was part of a previously published COS on COVID-19. The next step in this COS development exercise will be to establish the instruments that are most appropriate to measure these core outcomes. This international consensus-based COS should provide a framework for standardised assessment of adults with post-COVID-19 condition, aimed at facilitating clinical care and research worldwide.
UR - http://www.scopus.com/inward/record.url?scp=85132508166&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(22)00169-2
DO - 10.1016/S2213-2600(22)00169-2
M3 - Review article
C2 - 35714658
SN - 2213-2600
VL - 10
SP - 715
EP - 724
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 7
ER -